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Background: Insomnia causes severe distress in patients with breast cancer who receive chemotherapy. Few
studies have focused on using objective methods to assess sleep. This study explored the quality of sleep and
related factors in patients with breast cancer during chemotherapy.
Methods: The participants were 16 women with stage I or II breast cancer receiving their third cycle of
chemotherapy with cyclophosphamide, epirubicin and fluorouracil, or cyclophosphamide, methotrexate and
fluorouracil. The effects of chemotherapy on sleep were assessed on the 8th and 9th days of the third cycle, i.e.
the active phase in terms of side effects, and the last 2 days before the start of the fourth cycle for comparison.
Instruments used to assess sleep quality and related factors included actigraphy, the Hospital Anxiety and
Depression Scale (HADS), the Symptom Distress Scale (SDS), the Fatigue Visual Analogue Scale (FVAS), the
Epworth Sleepiness Scale (ESS), and sleep logs.
Results: During the active phase, patients showed an anxiety tendency with an average HADS score of 7.8 (
3.8. The average FVAS score was 4 ( 2, indicative of mild fatigue, and SDS score (1.8 ( 0.3) also indicated
mild symptom distress. The number of awakenings each night was 2.2 ( 1.6 by sleep logs, and the total time
spent awake during these episodes was 47.8 ( 26.1 minutes by Actiwatch. Sleep efficiency measured by
Actiwatch in the active phase was 82.1 ( 9.4% below the normal limit. Daytime sleepiness assessed by ESS
showed mild sleepiness (6.0 ( 3.5) in the active phase.
Conclusion: The study showed poor sleep quality and daytime sleepiness in patients with breast cancer
during the active phase of chemotherapy. Chemotherapy may bring symptom distress to patients and adversely
influence sleep quality. [J Formos Med Assoc 2006;105(1):64–69]
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Chemotherapy is one of the main treatments for
breast cancer. Insomnia causes severe distress in
patients with cancer who receive chemotherapy.1
Sleep disturbances not only induce discomfort in
patients and interfere with their daily activities, but
also adversely influence their will to receive treat-
ment and, consequently, treatment outcome. There
have been few studies of sleep quality in patients
with breast cancer receiving chemotherapy. Berger
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and Higginbotham found that total sleep time and
sleep latency were increased during chemotherapy
in patients with breast cancer, but their sleep effi-
ciency was still normal.2 Piper reported that pro-
longed total sleep time, difficulty in falling asleep,
and frequent sleep interruptions and insomnia in
patients receiving chemotherapy made it difficult
for them to obtain good sleep quality.3 Other fac-
tors such as anxiety, depression, fatigue, symptom
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Subjects
Female patients with stage I or II breast cancer
receiving either a regimen of cyclophosphamide,
epirubicin and fluorouracil (CEF) or cyclophospha-
mide, methotrexate and fluorouracil (CMF) were
included. Both groups were in their third cycle of
adjuvant chemotherapy. Subjects were between
18 and 65 years old, and were recruited from on-
cology clinics, general surgery clinics and the chem-
otherapy rooms of two medical centers. Patients
with psychiatric or neurologic diseases that could
cause sleep problems or result in tremor or limb
paralysis were excluded.
Questionnaires
Hospital Anxiety and Depression Scale (HADS)
The HADS, developed by Zigmond and Snaith in
1983, is used to assess the degree of anxiety and
depression of general medicine outpatients. A high-
er total score indicates a higher degree of anxiety
or depression. The Chinese version of the HADS,
authorized by the Nfer-Nelson company, was used
in this study. Chen et al used the Chinese version
of the HADS in a study of 90 cancer patients, and
found that Cronbach’s _ for the degree of anxiety
and degree of depression was 0.82 and 0.77,
respectively, indicating the validity and reliability
of the instrument.17
Fatigue Visual Analogue Scale (FVAS)
The subjective degree of fatigue of patients was
measured on a 10-cm straight line. The left end of
the line represented “no fatigue”, and the right end
of the line represented “most fatigue”. At the time
of assessment, the patient indicated her degree of
fatigue on the straight line and the researcher as-
sessed the degree of fatigue in the patient by meas-
uring the distance from the left edge to the point
where the patient marked. VAS has been extensively
used for the assessment of various feelings or emo-
tions in previous studies and has been found to be
reliable and valid.18,19
Symptom Distress Scale (SDS)
We used a Chinese version of the SDS developed
by McCorkle and Young and modified by Lai.20 The
distress, environment, age, education, marital sta-
tus and menstruation could also influence sleep
quality. Insomnia is highly correlated with the se-
verity of anxiety and depression.4–6 A high degree
of anxiety and depression would increase sleep la-
tency and make it difficult to fall asleep.7–9 A high
degree of fatigue would result in poor daytime
function.10
Conventional sleep studies have mostly as-
sessed sleep quality with subjective questionnaires
and lacked objective data. Polysomnography is the
standard measure for objective sleep assessment
but it has some limitations, especially when
used to assess insomnia.11,12 For example, it can
only be performed in a sleep laboratory where
the unfamiliar environment is likely to adversely
influence natural sleep. It also has a very high
cost which may limit repeated measurements.
Actiwatch (Cambridge Neurotechnology Ltd,
Cambridge, UK) is a noninvasive device to moni-
tor physical activity. Data recorded by Actiwatch
can be transformed into sleep parameters.13–15 Some
studies indicated high correlation between actig-
raphy and polysomnography (r = 0.85–0.95).13,16
This study used both subjective questionnaires
and Actiwatch to assess sleep quality and related
factors in patients with breast cancer during chemo-
therapy.
Methods
A prospective, descriptive, and repeated measures
method was used in this study. The first period of
data collection was during the 8th and 9th days of
the third cycle of adjuvant chemotherapy, which
was defined as the active period because both
acute and delayed side effects are known to be
most frequent and prominent during this period.
The second period of data collection was 2 days
before the fourth cycle of adjuvant chemotherapy,
which was defined as the recovery period because
most of the side effects from chemotherapy gener-
ally improve during this period. Both subjective
and objective data from the two periods were
compared.
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SDS assesses the degree of uncomfortable com-
plications in patients receiving chemotherapy.
Twenty-two symptoms are addressed in the SDS,
including nausea and vomiting, a change in ap-
petite, insomnia, pain, fatigue, a change in bowel
habits, dysuria, dyspnea, cough, abdominal disten-
sion, dry mouth, sore throat, ulcer, irritability, un-
stable emotions, a change in appearance, bleeding,
fever and chillness, numbness, chest tightness,
and gastric burning sensations. The symptoms
were recorded on a scale of 1 (no complications)
to 5 (very serious complications). The internal con-
sistency of the original SDS was 0.83, with a Cron-
bach’s _ of 0.78. The Cronbach’s _ of the Chinese
version as modified by Lai was 0.91.20
Actigraphy
Actiwatch is an activity monitor, designed for long-
term monitoring of gross motor activity in human
subjects.13–15 It contains an accelerometer that
is capable of sensing any motion with a minimal
resultant force of 0.01 g. It is necessary to load a
series of commands into the activity monitor pri-
or to data collection. These settings lay in sampling
parameters such as start time and date, and the
period of time between samples known as the
epoch length. Other settings include an identifica-
tion string, gender and age data for the subject.
Once the settings have been made, the activity
monitor is ready to be placed on the subject. After
data collection has been completed, the stored
activity data are downloaded to a PC for analysis
and permanent storage. All communication with
Actiwatch is accomplished through an Actiwatch
reader that is connected to a PC. Actiwatch Sleep
Analysis (Cambridge Neurotechnology Ltd), a
Microsoft Windows version software, is pro-
grammed for the transformation and analysis of
sleep data acquired from Actiwatch. These data
include sleep latency, total sleep time, and sleep
efficiency through records of activity associated
with the record of the sleep logs.
Studies have shown actigraphy to be a valid and
reliable tool for measuring activity and sleep in a
variety of healthy and sick populations.3,13 Al-
though actigraphy is a sensitive noninvasive tool
that is easy to use, some researchers have found
that actigraphy overestimated sleep quality such
as total sleep time and sleep efficiency, and rec-
ommend that subjective data should be used as an
adjunct to actigraphic data to assess sleep quality
in order to increase accuracy.11,14
Sleep logs
Sleep logs were used to record related sleep infor-
mation of the participants, including time to bed,
time to wake up, total sleep time, sleep latency and
sleep quality by self-report. Sleep logs have been
shown to be valid and useful in previous studies
of sleep-related clinical problems.12,21 The Chinese
version of the sleep log used in this study was a
product issued by the International Foundation for
Mental Health and Neurosciences in 2001.15 We
also asked participants to make a note in their sleep
logs when they removed or put on the Actiwatch.
Sleep logs provided information to assist in the
analysis of actigraphy data and in the analysis of
subjective sleep quality from patients’ self-reports.
Epworth Sleepiness Scale (ESS)
Johns developed the ESS in 1991.22 It assesses the
individual’s degree of daytime sleepiness during
eight different phases of daily life. Each question
is measured on a 0–3 point scale scored as follows:
0 = no chance of dozing; 1 = slight chance of
dozing; 2 = moderate chance of dozing; 3 = high
chance of dozing. The possible score on the ESS
ranges from 0 to 24. Scores exceeding 6 points in-
dicate slight sleepiness. Scores exceeding 10 points
indicate moderate sleepiness and scores exceeding
16 points indicate high levels of sleepiness. The
higher the score, the more likely the patient is to
fall asleep or to suffer from sleeping problems.13,23
Data collection and analysis
All participants gave informed consent before their
entry into the study. Questionnaires including
relevant demographic information and the HADS,
sleep logs, and FVAS were first administered to each
patient. Then patients were trained to maintain the
HADS, sleep logs, and FVAS data. They were also
trained to use the Actiwatch. Actiwatch Sleep soft-
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ware was used to compute the total sleep time,
sleep efficiency, number of awakenings during
sleep and total time spent awake. Descriptive sta-
tistical analyses, Spearman’s rank-order correlation,
Mann-Whitney U test, and the Wilcoxon signed-
rank test were performed using SPSS for Windows
version 10.0 (SPSS Inc, Chicago, IL, USA).
Results
Sixteen patients met the research criteria and were
included in the study. Their mean age was 45
years (range, 29–59 years); 50% of patients were
college graduates, 43.8% were unemployed, and
75% were married. Regular menstruation was
reported by 62.5% of patients (although none re-
ported menstruation at the time of data collection).
Seven patients received a 21-day cycle CEF regimen,
with the drugs injected on day 1. Nine patients re-
ceived CMF chemotherapy, of whom seven were
on a 28-day cycle with injections on days 1 and 8,
and the other two were on a 21-day cycle with in-
jections on day 1 (Table 1).
Psychologic and physical distress
During the active phase of chemotherapy, the mean
HADS score for anxiety was 7.81 ( 3.76, indicat-
ing increased anxiety in patients. The mean FVAS
score was 4 ( 2, indicating a mild degree of fatigue.
Comparison of mean SDS scores between the ac-
tive and recovery phases of chemotherapy using
the Wilcoxon signed-rank test revealed a signifi-
cant difference (Z = –3.260, p < 0.01) (Table 2). A
greater degree of symptom distress was reported
during the active phase than during the recovery
phase. The top three causes of symptom distress
during the active phase were change in appearance
(2.8 ( 1.1), fatigue (2.6 ( 0.9), and reduced appe-
tite accompanied by nausea (2.6 ( 1.2). The top
three causes of symptom distress during the re-
covery phase were fatigue (2.2 ( 1.0), change in
appearance (2.0 ( 1.0), and the feeling of thirst
(1.9 ( 0.6).
Sleep quality
Mean sleep latency during the active phase was
35.1 ( 30.5 minutes as measured by sleep logs,
and 22.7 ( 24.6 minutes as measured by Actiwatch.
The number of awakenings during the sleeping
period as measured by sleep logs was 2.2 ( 1.6.
The total time spent awake during the sleeping pe-
riod as measured by Actiwatch was 47.8 ( 26.1
minutes. Sleep efficiency during the active phase
as measured by actigraphy was 82.1 ( 9.4%. The
ESS score for daytime drowsiness during the active
phase was 6 ( 3.5, indicative of a light doze. In
contrast, patients had a lower ESS score of 4.3 (
3.6 during the recovery phase (Table 2). These re-
sults indicate that patients suffered from daytime
drowsiness during the active phase but not during
the recovery phase (Z = –1.97, p < 0.05, Wilcoxon
signed-rank test). The degree of symptom distress
correlated positively with the scores of daytime
sleepiness (r = 0.787, p < 0.01, Spearman’s rank
correlation), i.e. greater distress levels were associ-
ated with greater daytime drowsiness. The sleep
Table 1. Characteristics of 16 patients with
breast cancer
Variable n (%)
Age
) 40 yr 6 (37.5)
41–50 yr 5 (31.3)
51–65 yr 5 (31.3)
Education
) Junior high school 2 (12.5)
Senior high school 3 (18.8)
University 8 (50.0)
Graduated 3 (18.8)
Marital status
Single 4 (25.0)
Married 12 (75.0)0
Menstruation
Menopause 6 (37.5)
Normal 10 (62.5)0
Chemotherapy regimen
CEF 7 (43.8)
CMF 9 (56.2)
CEF = cyclophosphamide, epirubicin, fluorouracil; CMF =
cyclophosphamide, methotrexate, fluorouracil.
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quality scale score during the active phase was 2.8
( 0.5, indicating that most patients considered their
sleep quality to be between “common” and “bad”.
Patients enjoyed better sleep quality during the
recovery phase than during the active phase (Z =
–2.02, p < 0.05, Wilcoxon signed-rank test).
Discussion
The study found that during the active phase of
chemotherapy, when side effects are acute, patients
demonstrated a longer period of subjective sleep
latency than after recovery from treatment. A sim-
ilar observation that more than half of patients had
a longer period of sleep latency than healthy con-
trols has been reported.5 Cohen et al further sug-
gested that long sleep latency indicated poor sleep
quality during the active phase of chemotherapy.24
We also found that the number of sleep interrup-
tions and waking hours increased during the ac-
tive period of chemotherapy. Patients woke more
often at night during the active phase of chemo-
therapy.5 These findings confirm that chemothera-
py increases the number of sleep interruptions
during the active period.
The sleep efficiency rate of 82.1% as measured
by the Actiwatch during the active phase of chem-
otherapy in this study is indicative of decreased
sleep efficiency. This is consistent with another re-
port that half of the patients had a sleep efficiency
rate of less than the normal 85% during active
chemotherapy.5
In this study, daytime drowsiness was more
common during the active phase than during the
recovery phase of chemotherapy. This result is con-
sistent with the study of Berger and Farr, who found
that patients demonstrated a low degree of activity
in the daytime and took frequent naps during the
active phase of chemotherapy.10 These findings
show that chemotherapy affects patients’ daytime
function by causing drowsiness. Chemotherapy is,
thus, associated with poor sleep quality and may
also have psychologic impacts associated with day-
time drowsiness, as previously reported by Piper.3
We found that sleep quality was negatively
affected during the active phase of chemotherapy.
Patients enjoyed better sleep quality during the re-
covery phase than during the active phase. Further
research is needed to investigate the effects of
different phases and regimens of chemotherapy.
The results of such studies should be used to de-
Table 2. Psychologic and physical distress and sleep quality in 16 patients with breast cancer during
the active and recovery periods of the third cycle of chemotherapy
Subjective (mean ( SD) Objective (mean ( SD)
Active Recovery Z Active Recovery
Psychologic and physical distress
Anxiety measured by HADS 7.8 ( 3.8 .7.3 ( 3.4 – –
Depression measured by HADS 4.8 ( 2.7 .5.3 ( 3.3 – –
Fatigue measured by FVAS 4 ( 2 3.6 ( 20 – –
Symptom distress measured by SDS 39.8 ( 7.20 30.6 ( 50.. –3.26* – –
Sleep quality
Actual sleep time (min) 446.5 ( 69.10 466.1 ( 67.5 395.1 ( 73.80 391.2 ( 72.90
Sleep latency (min) 35.1 ( 30.5 023.1 ( 18.3 22.7 ( 24.6 23.6 ( 26.2
Number of awakenings 2.2 ( 1.6 00.2 ( 1.0
Total time awakened (min) 47.8 ( 26.1 .56.4 ( 31.3
Sleep efficiency (%) 92.8 ( 5.20 95.3 ( 3.3. 82.1 ( 9.40 79.9 ( 9.70
Daytime sleepiness 0.6 ( 3.5 .4.3 ( 3.6 –1.97† – –
Subjective sleep quality 2.8 ( 0.5 .3.3 ( 0.7 –2.02† – –
*p < 0.01, †p < 0.05 (Wilcoxon signed-rank test). HADS = Hospital Anxiety and Depression Scale; FVAS = Fatigue Visual Analogue
Scale; SDS = System Distress Scale.
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sign effective strategies to alleviate these adverse
effects.
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